The Use of mRNA for an HIV Envelope Vaccine (R43/R44) | Apply Online

Opportunity Summary:

The funding opportunity titled "The Use of mRNA for an HIV Envelope Vaccine (R43/R44)" (Funding Opportunity Number PA 16-207) is a discretionary NIH grant program under the U.S. Department of Health and Human Services (HHS-NIH) that targets small businesses interested in advancing HIV vaccine technology. It uses the Small Business Innovation Research (SBIR) mechanism, specifically the R43 and R44 award types, which are designed to help small companies move promising early-stage biomedical innovations from concept to development and, ultimately, toward real-world use. In practical terms, this FOA is meant to push industry-driven innovation while still supporting the kind of rigorous preclinical and early translational work that is needed before a vaccine platform can be tested in humans.

The core scientific focus is on developing novel messenger RNA (mRNA) vaccine platforms that express HIV envelope (Env) antigens. HIV Env is the viral surface protein complex that the immune system "sees" and that many vaccine strategies aim to target, because it is central to viral entry into host cells and is a key target for neutralizing antibodies. This FOA explicitly encourages two mRNA approaches: direct (non-amplifying) mRNA vaccines and self-amplifying mRNA (saRNA) vaccines. Direct mRNA typically delivers an engineered mRNA encoding the desired antigen so host cells produce the protein for a period of time. Self-amplifying mRNA platforms, by contrast, include additional replicative elements (often derived from alphavirus replicon concepts) that can amplify the RNA inside cells, potentially achieving similar antigen expression with lower dose levels and different expression kinetics. The announcement is essentially asking small businesses to innovate in this space with platforms and formulations that can realistically be advanced into clinical research settings.

A key requirement embedded in the description is that the proposed technologies should be suitable for use in clinical research, which signals that the NIH is not looking only for basic science ideas. Applicants are expected to think about features that matter for translation, such as product design that can be manufactured with consistent quality, deliverability and stability appropriate for clinical use, and a development path that anticipates preclinical safety and immunogenicity needs. Although the FOA summary does not spell out specific milestones, the SBIR structure typically implies Phase I (R43) feasibility and proof-of-concept work, followed by Phase II (R44) further development, optimization, and preparation for next-stage testing. The inclusion of both R43 and R44 suggests NIH interest in supporting projects across that progression, from early feasibility through more advanced development.

This opportunity is limited to eligible small business applicants, reflecting the SBIR program's purpose of stimulating technological innovation and strengthening commercialization pathways within the U.S. small business sector. Commercial potential is emphasized directly in the description, meaning applicants should frame their work not only as a scientific advance but also as a platform with a plausible route to broader adoption. For an mRNA-based HIV Env vaccine platform, that could mean demonstrating advantages such as improved antigen design or presentation, better immune responses, improved tolerability, lower dose requirements, scalable manufacturing processes, better stability and distribution characteristics, or delivery systems that enable consistent in vivo expression. NIH interest in commercial potential also implies that applicants should consider intellectual property strategy, competitive landscape, and how the platform could attract follow-on investment or partnerships required for clinical advancement.

Administratively, the FOA is categorized as a grant in the health domain, with CFDA numbers 93.855 and 93.856, which align with NIH HIV/AIDS-related research and related infectious disease research activities. The FOA was created and posted on April 19, 2016, with an original and current closing date listed as April 5, 2019. The listing does not provide an award ceiling or the expected number of awards in the provided data, so applicants would typically look to the full NIH FOA text and associated NIH SBIR guidance for budget caps, project period limits, eligibility details, and review criteria.

Overall, PA 16-207 is best read as a targeted call for small businesses to build and mature mRNA and self-amplifying mRNA vaccine platforms specifically aimed at HIV Env, with an emphasis on realistic clinical research suitability and clear commercialization potential. It sits at the intersection of platform technology development (mRNA/saRNA delivery, expression, and manufacturing) and HIV immunogen design (Env-focused vaccine concepts), encouraging applicants to propose solutions that can move beyond laboratory promise and toward practical clinical evaluation.

Browse more opportunities from the same agency: HHS-NIH11

Browse more opportunities from the same category: Health

Next opportunity: BLM-WO, Western States Collaborative Sage-Grouse Habitat Conservation

Previous opportunity: Survey of Prison Inmates Statistical Support Center (SPISSC)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 16 207

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 16 207) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 207", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.